Site Neutral Payments Explained for ASC Owners and Hospital CFOs
How the CY2026 Medicare rule narrows the ASC-HOPD payment gap, and what it means for budgets, contracts and joint ventures.
Site neutral payments are reshaping ASC and HOPD reimbursement under the CY2026 Medicare rule. What owners and CFOs need to confirm before 2027.

Site neutral payments are the Medicare policy direction that pays the same rate for the same procedure no matter where it is performed, and the CY2026 rule moved 560 procedures onto the ASC covered list as part of that shift (CMS, November 2025). For an industry built on the price gap between a hospital outpatient department and a surgery center, that direction changes the math on every new procedure, every payer contract and every joint venture conversation happening right now.
What "site neutral" actually means
Medicare has historically paid more for the same procedure in a hospital outpatient department (HOPD) than in an ASC, and more again in an inpatient setting. Site neutral payments move toward one rate for one procedure, regardless of where a patient has it done (MedPAC). The CY2026 rule did not finish that work. It advanced it in one specific place: drug administration services in excepted off-campus hospital departments are now paid at the physician fee schedule rate instead of the higher hospital rate (CMS, November 2025).
That is a narrow change on paper. The direction behind it is not narrow. Every rule cycle that treats site of service as less relevant to the payment amount is a rule cycle that makes the ASC case for a procedure stronger, because the ASC was already the lower-cost setting for Medicare, commercial payers and patients. The 560 procedures added to the covered list, 271 of them freed from the inpatient only list, are the visible part of the same policy logic (CMS, November 2025). Read the detail on that list in The CMS 2026 Final Rule for ASCs: 560 Procedures Added, the Inpatient Only List Phased Out.
What changed in the CY2026 rule
The table below is the rule in five lines. Confirm the CY2027 update, published each November, before you build next year's budget; a conversion factor or a covered-list change moves every number below it.
| Item | What changed |
|---|---|
| Payment update | ASC and HOPD rates rose about 2.6 percent for centers meeting ASC Quality Reporting requirements |
| ASC covered procedures list | 560 surgical procedures and 35 ancillary services added, including 271 codes removed from the inpatient only list |
| Inpatient only list | Being phased out over three years starting in 2026, musculoskeletal procedures first |
| Site neutrality, drug administration | Excepted off-campus hospital departments now paid at the physician fee schedule rate instead of the hospital rate |
| ASC Quality Reporting penalty | Centers that miss reporting requirements lose 2.0 percentage points off the annual payment update (CMS) |
Two rows matter more than they look. The quality reporting penalty is the enforcement mechanism behind the 2.6 percent update: miss the submission and you do not get a smaller increase, you get a worse one, 2.0 points under what a compliant center receives. And the inpatient only phase-out is scheduled, not optional. Each year for three years, more procedures move, and each one needs a contribution margin calculation before it goes on your schedule, not after.
What it means for hospital CFOs
Site neutrality squeezes the HOPD side of a health system's business on the exact procedures where ASCs are already built to compete. A hospital that has been running total joints or GI cases through its outpatient department at the higher HOPD rate is watching that premium shrink, procedure by procedure, rule cycle by rule cycle. The response most systems are choosing is not to fight the direction, it is to own ASC capacity: about 38 percent of ASC revenue already sits outside pure physician ownership, in hospital, corporate and joint venture structures, against 62 percent physician-owned (MedPAC, industry reports). A joint venture converts a shrinking HOPD margin into a share of a growing ASC one. The reimbursement mechanics behind that decision are in ASC vs HOPD: How Reimbursement Differs for the Most Common Procedures.
The timing question for a CFO is not whether to respond to site neutrality. It is whether to build, buy or partner before the next three annual rule cycles finish moving the inpatient only list, or after. Certificate of need law is part of that timing: 35 states plus the District of Columbia still run some form of CON program, and several exempt ASCs or apply lighter review (AHPA, NCSL, 2025). A CON state adds months to any build-or-buy decision that a non-CON state does not.
What it means for ASC owners
A new covered procedure with no attached commercial rate is not revenue. It is a negotiation. Most commercial payers price ASC procedures as a multiple of the Medicare rate, and a code that just moved off the inpatient only list often has no commercial ASC rate on file at all. The center that walks into that conversation with a cost per case for the procedure gets a rate. The center that walks in with a volume estimate gets a number the payer already had.
Before adding any of the 560 newly covered procedures to a surgeon's block, three questions answer whether it belongs there:
- What does the procedure cost this center to perform, by direct supply, implant and labor minutes, not by the national average supply ratio.
- What does each payer in the mix currently pay for it, and is that rate a negotiated ASC rate or an unpriced Medicare multiple that needs a call.
- What contribution margin does the procedure clear after both of those numbers are real, and does that margin justify the block time it would take from a case already on the schedule.
None of those questions get easier because Medicare opened the door. They get answered the same way every procedure on your schedule should be answered: by costing the case before you price it, a process covered in detail on ASC Benchmarks 2027.
The gap between the policy and your pro forma
Site neutral payments and the covered-list expansion are addressable market, not booked revenue. The CY2026 rule made a wider range of procedures payable in an ASC. It did not make your center's supply chain, staffing model or payer contracts ready to deliver them at a margin. A procedure that is profitable at the national average supply ratio can be under water at your center's actual implant invoice, and the only way to know before you schedule the first case is to run the numbers, not the rule.
The same logic applies to the denial and AR side of the ledger. A new covered procedure with no commercial rate on file is also a procedure with no prior authorization history and no denial pattern yet. Track it from the first case, not the fiftieth, using the same revenue cycle benchmarks you already hold the rest of your schedule to; see ASC Revenue Cycle Management: Denial Rates, Days in AR and the Benchmarks to Hold for the denial rate and AR thresholds worth watching. And because a new procedure competes for the same block minutes as everything already on the schedule, utilization discipline matters more with every covered-list expansion, not less; the operating room KPIs that govern that competition are in Operating Room KPIs: The Key Performance Indicators Surgical Services Directors Track.
What to do this quarter
Site neutral payments and the covered-list changes will keep arriving every November. The centers that benefit are the ones that treat each rule cycle as a costing exercise, not an announcement. Three steps for this quarter:
- List every procedure your surgeons already perform in a hospital setting that moved onto the ASC covered list in 2026, and cost each one using actual consumption and implant invoices before scheduling a single case.
- Pull the commercial rate on file for each of those procedures by payer. Where there is no rate, or the rate is an unpriced Medicare multiple, put that payer on the contracting list before the first patient is booked.
- Confirm the CY2027 final rule, published each November, against this quarter's budget. A conversion factor change, a further covered-list addition or the next phase of the inpatient only phase-out can move a number you already built a pro forma around.
Related reading
- ASC Benchmarks 2027
- The CMS 2026 Final Rule for ASCs: 560 Procedures Added, the Inpatient Only List Phased Out
- ASC vs HOPD: How Reimbursement Differs for the Most Common Procedures
- Operating Room KPIs: The Key Performance Indicators Surgical Services Directors Track
- The ASC resource hub: every Sigmatic guide on ambulatory surgery centers
Make your ASC more profitable
Sigmatic is a team of ASC consultants who use our own technology to manage surgery centers: better margins, better workflows, and a real-time view of cost per case and utilization that keeps the gains in place. If the numbers in this article look like your center, book a free 30-minute consultation and we will go through your own figures and show you where the margin is. Read the ASC Benchmarks 2027 guide, grab the free PDF, The 2027 ASC State of the Union: maximizing profit on razor-thin margins, from the form on this page, or email [email protected].
Free guide
The 2027 ASC State of the Union: Maximizing profit on razor-thin margins
16 pages of charts: the market, the 2026 reimbursement rules, the benchmarks that separate a 13 percent margin from a 37 percent one, a case costing method you can run this month and a 90-day plan.
Before you go
Want a more profitable ASC?
Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.
Make your ASC more profitable.
A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.